Sep 22, 2022 by Natalie ForbesThis Company Could Beat Out Teladoc, and It's Not AmazonA potentially disruptive business model is finding its legs in the post-pandemic healthcare landscape.
Sep 15, 2022 by Natalie ForbesWhy This Monster Stock's Recent Blunders Might Not MatterStrong sales of its top blockbuster overcome some weaker pipeline results.
Sep 7, 2022 by Natalie ForbesMerck's Deal With Seagen May Have Fallen Through. Now What?A steep valuation may force Merck to look elsewhere for portfolio growth.
Sep 1, 2022 by Natalie ForbesThis Stock Soared in August. Is It Still a Buy?This industry-leading company can weather a challenging operating environment.
Aug 31, 2022 by Natalie ForbesWhat This News Might Mean for AmgenThe company finds some protection against measures aimed to cut industry drug prices.
Aug 21, 2022 by Natalie ForbesWhich Growth Stock Is a Better Buy Right Now -- AbbVie or InMode?These beaten-down stocks share a favorable outlook for their aesthetic segments.
Aug 17, 2022 by Natalie ForbesHow Eli Lilly Is Thinning Out the CompetitionThe company sees good market signals from its recently launched potential blockbuster drug.
Aug 5, 2022 by Natalie ForbesShould You Really Care About This Company's Short-Term Success?Abbott Laboratories' growth looks much less impressive after removing sales from COVID-19 diagnostics.
Aug 2, 2022 by Natalie ForbesWhat 1 Key COVID Drug's News Might Mean For PfizerOral antiviral Paxlovid saw stronger-than-expected sales in the first half of the year, but still hasn't captured the international markets.
Jul 30, 2022 by Natalie ForbesHow This Multibillion-Dollar Company Is Shaking Off the CompetitionThe company has posted growth despite lower demand for several key products.
Jul 28, 2022 by Natalie ForbesThese New Blockbusters Could Fill Bristol-Myers Squibb's Revenue GapA looming patent cliff puts pressure on the company's newest products.
Jul 24, 2022 by Natalie ForbesHow Medtronic Is Strengthening Its Robotics PortfolioAdvanced technology in spinal surgery is helping the company build its case in a fast-growing market.
Jul 21, 2022 by Natalie ForbesWhat This FDA Delay Means for NovartisThe FDA defers action on a highly anticipated potential blockbuster drug for cancer.
Jul 21, 2022 by Natalie ForbesHow These Acquisitions Are Changing the Outlook for Bristol Myers SquibbThe company is reshaping and expanding its oncology portfolio.
Jul 13, 2022 by Natalie ForbesWhy This Company Still Has a Long Runway for GrowthA competitive labor landscape makes this company's offerings even more attractive.
Jul 11, 2022 by Natalie ForbesHow Its New Vaccine Could Propel GSK's GrowthGSK leads the race to deliver a vaccine for an untreated infectious disease.
Jul 9, 2022 by Natalie ForbesThis Company Could Ease the Pain in a Bear MarketNew product candidates aim to diversify into areas with a large unmet medical need.
Jul 1, 2022 by Natalie ForbesWhy This Company Could See Long-Lasting Tailwinds Despite the Bear MarketAn industry-leading company looks past COVID-19 to future growth.
Jun 27, 2022 by Natalie ForbesHow Pfizer Plans to Unlock Another Mass-Market VaccineThe company turns its attention to another infectious disease that lacks a vaccine.
Jun 25, 2022 by Natalie ForbesWhy Sanofi May Be a Frontrunner in Endemic COVID-19There is a promising outlook for its next generation of vaccines.
